aTyr Pharma, Inc. Stock 12‑Month Price Target Raised to $3.2, Implies 1757% Upside
Analysts raised aTyr Pharma's 12-month price target to $3.2, up from $2.83, with estimates ranging from $1 to $7. This implies a 1757% upside from the Oct. 21 closing price. The consensus rating remains 'Buy' among 7 analysts, with 3 Buys and 4 Holds.
How this was made
The 30-second read
Why it matters
The target raise signals analyst optimism but does not constitute a material catalyst for the stock.
Market read
Limited relevance; the news is a modest analyst update for a micro‑cap.
What to watch
No new clinical data or regulatory events accompany the target change.
Background
aTyr Pharma is a small biotech listed on NASDAQ; price‑target updates are routine analyst activity.
Ticker impact
Analysts raised the average 12‑month price target for aTyr Pharma to $3.2, implying a 1757% upside.
possible modest upside as investors chase the large implied upside
The target change is new but the company is a micro‑cap; the magnitude of the implied upside is high but the absolute dollar impact is small.
Market effects
Minimal; aTyr operates in biotech where analyst target revisions are common.
None
Low
Counterpoint
The huge implied upside may be unrealistic; price could remain flat or decline on profit‑taking.
Key entities
- companyaTyr Pharma, Inc.
Biotech firm whose price target was raised.